| Marc Scott Leder, MD | |
|
4363 All Seasons Dr Ste 100, Hilliard, OH 43026-2050 | |
| (614) 355-5900 | |
| Not Available |
| Full Name | Marc Scott Leder |
|---|---|
| Gender | Male |
| Speciality | Pediatrics - Pediatric Emergency Medicine |
| Location | 4363 All Seasons Dr Ste 100, Hilliard, Ohio |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356333769 | NPI | - | NPPES |
| 0920981 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2080P0204X | Pediatrics - Pediatric Emergency Medicine | 35064844 (Ohio) | Primary |
| Entity Name | Pediatric Academic Association, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063419943 PECOS PAC ID: 2961306774 Enrollment ID: O20031124000198 |
News Archive
The Baylor College of Medicine Human Genome Sequencing Center has standardized its target enrichment human disease research studies on Roche NimbleGen Sequence Capture Exome technology. The Baylor HGSC will sequence over 5,000 exomes in the next two years to identify genetic variants underlying multiple human diseases and will employ NimbleGen SeqCap EZ Exome and customized NimbleGen exome designs as the exome capture technology of choice. More than 15 different diseases will be investigated by Baylor HGSC, including brain, liver, pancreatic, colon, ovarian and bladder cancers, heart disease, diabetes, autism, and other inherited diseases with the goal of better understanding causative mutations and their impact on these diseases.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the gastric cancer drug market - driven by the launch of several targeted agents over the next few years - will more than double from approximately $700 million in 2008 to nearly $1.5 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
People given a biological and genetics-based explanation for the causes of anorexia nervosa were less likely to blame people with anorexia for their illness than those given a sociocultural explanation, a University of North Carolina at Chapel Hill study found.
Decision Resources has expanded its disease-level coverage of the Treatment Algorithms Insight Series, which examines U.S. physicians' prescribing behavior, to provide a quantitative analysis of an agent's penetration into each line of therapy.
› Verified 3 days ago
| Entity Name | Children's Anesthesia Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629020680 PECOS PAC ID: 4587568993 Enrollment ID: O20031126000097 |
News Archive
The Baylor College of Medicine Human Genome Sequencing Center has standardized its target enrichment human disease research studies on Roche NimbleGen Sequence Capture Exome technology. The Baylor HGSC will sequence over 5,000 exomes in the next two years to identify genetic variants underlying multiple human diseases and will employ NimbleGen SeqCap EZ Exome and customized NimbleGen exome designs as the exome capture technology of choice. More than 15 different diseases will be investigated by Baylor HGSC, including brain, liver, pancreatic, colon, ovarian and bladder cancers, heart disease, diabetes, autism, and other inherited diseases with the goal of better understanding causative mutations and their impact on these diseases.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the gastric cancer drug market - driven by the launch of several targeted agents over the next few years - will more than double from approximately $700 million in 2008 to nearly $1.5 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
People given a biological and genetics-based explanation for the causes of anorexia nervosa were less likely to blame people with anorexia for their illness than those given a sociocultural explanation, a University of North Carolina at Chapel Hill study found.
Decision Resources has expanded its disease-level coverage of the Treatment Algorithms Insight Series, which examines U.S. physicians' prescribing behavior, to provide a quantitative analysis of an agent's penetration into each line of therapy.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Marc Scott Leder, MD 700 Children's Drive, Columbus, OH 43205-2664 Ph: (614) 722-2000 | Marc Scott Leder, MD 4363 All Seasons Dr Ste 100, Hilliard, OH 43026-2050 Ph: (614) 355-5900 |
News Archive
The Baylor College of Medicine Human Genome Sequencing Center has standardized its target enrichment human disease research studies on Roche NimbleGen Sequence Capture Exome technology. The Baylor HGSC will sequence over 5,000 exomes in the next two years to identify genetic variants underlying multiple human diseases and will employ NimbleGen SeqCap EZ Exome and customized NimbleGen exome designs as the exome capture technology of choice. More than 15 different diseases will be investigated by Baylor HGSC, including brain, liver, pancreatic, colon, ovarian and bladder cancers, heart disease, diabetes, autism, and other inherited diseases with the goal of better understanding causative mutations and their impact on these diseases.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the gastric cancer drug market - driven by the launch of several targeted agents over the next few years - will more than double from approximately $700 million in 2008 to nearly $1.5 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
People given a biological and genetics-based explanation for the causes of anorexia nervosa were less likely to blame people with anorexia for their illness than those given a sociocultural explanation, a University of North Carolina at Chapel Hill study found.
Decision Resources has expanded its disease-level coverage of the Treatment Algorithms Insight Series, which examines U.S. physicians' prescribing behavior, to provide a quantitative analysis of an agent's penetration into each line of therapy.
› Verified 3 days ago
Dr. Jeffrey W Crecelius, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 3855 Trueman Ct, Hilliard, OH 43026 Phone: 614-777-1800 Fax: 614-777-1831 | |
Jennifer Lynn Burkam, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 4595 Trueman Blvd, Hilliard, OH 43026 Phone: 614-529-0771 Fax: 614-529-2370 | |
Dr. Paul Demoully Gilbert, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 2876 Hilliard Rome Rd, Hilliard, OH 43026 Phone: 614-529-4260 Fax: 614-529-4270 | |
Emily Kirstyn Gray, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 5510 Nike Dr, Hilliard, OH 43026 Phone: 614-529-4260 Fax: 614-529-4270 | |
Nathan Robert Richards, M.D. Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 3691 Ridge Mill Dr, Hilliard, OH 43026 Phone: 614-688-9220 | |
Dr. Robert W Snyder, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 3855 Trueman Ct, Hilliard, OH 43026 Phone: 614-777-1800 Fax: 614-777-1831 | |
Barbara Brooks Rayo, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 4595 Trueman Boulevard, Hilliard, OH 43026 Phone: 614-529-0771 Fax: 614-529-2370 |